Expert of the Month Interviews

Gene Therapy in Hemophilia experts from around the world provide updates monthly on the latest information and news.

This Month's Video: Five Year Data Confirms Stable FIX Expression and Sustained Reductions in Bleeding and Factor IX Use Following AMT-060 Gene Therapy in Adults with Severe or Moderate-severe Hemophilia B

Presented by: Wolfgang A. Miesbach, MD, PhD, Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main Germany.

Additional Updates

What to Expect at the upcoming ISTH Congress in Gene Therapy Hemophilia

Presented by: David Lillicrap, MD, FRCPC, Department of Pathology & Molecular Medicine, Queen's University, Kingston, Ontario

Highlights from the ASGCT 24th Annual Meeting

Presented by: Wolfgang A. Miesbach, MD, PhD, Department of Coagulation Disorders and the Comprehensive Care Haemophilia Centre, Goethe University Hospital, Frankfurt/Main Germany.

Hepatoxicity and Gene Therapy
 

Presented by: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC, Los Angeles, California.

Durability: Factor VIII and Factor IX Differences

Presented by: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Professor of Pediatrics (Clinical Scholar), Keck School of Medicine of USC, Los Angeles, California.
Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics, and uniQure, Inc.

Essential SSL